

Editorial

Micro RNAs in Human Papillomavirus Mediated Cervical Cancer

Niladri Ganguly*

School of Biotechnology, KIIT University, India

*Corresponding author: Niladri Ganguly, School of Biotechnology, KIIT University, Bhubaneswar 751024, India

Received: January 30, 2016; Accepted: February 08, 2016; Published: February 09, 2016

Editorial

Cervical cancer is the third most common cancer among women after breast and ovarian cancers. Almost 99% of cervical cancer samples contain Human Papillomavirus (HPV) DNA [1]. HPV is a non enveloped virus containing circular double stranded DNA as its genome. There are more than 100 types of HPV that have been identified till date. HPVs are classified into high risk types (HPV16, HPV18, and HPV31) or low risk types (HPV6, HPV11) depending on their ability to cause malignant tumor or benign warts/lesions respectively.

Micro RNAs (miR) are short single stranded RNA molecules of 20-24 nucleotides in length that are important molecules involved in epigenetic regulation of gene expression [2]. The inhibition of gene expression can be through transcriptional repression as well inhibition of translation by degradation of the corresponding messenger RNA. The genes encoding the miRs are found in the introns and intergenic sequences. Studies from different types of cancer samples using microarray expression analysis have clearly pointed to the role of miRs in cancer [3-6]. Mouse models having miRs overexpressed or ablated demonstrated the critical link between miRs and cancer progression.

Micro RNAs in Cervical Cancer

Since the discovery about the roles of miRs in influencing cancer phenotype, several studies have been done on the miRs that are aberrantly expressed in cervical cancer cells. The analysis of the expression profile analysis was reviewed recently by Sharma et al. [7]. The expression of miRs vary between different stages of Cervical Intraepithelial Neoplasia (CIN) i.e. CIN1, 2 and 3. Most miRs show a consistent up regulation or down regulation throughout the different CIN stages e.g. miR181, 191, 429, 214, 218, 143, 145, 497 etc. However, some miRs show an opposite trend while progressing from low grade (CIN1) to high grade (CIN3) cervical cancer e.g. miR 212, 132, 100 etc. The up regulation or down regulation of the respective miRs might be the cause of transition of the cancer from low to high grade. Thus miRs might be a useful marker for different stages of cervical cancer and to indicate the progression through different stages. Circulating miRs like miR-20a is one such biomarker for cervical cancer to found in lymph node [8].

Since miRs control the expression of several genes, studies have

identified the cellular target genes that are affected by specific miRs. Some miRs like miR-214 have five validated cellular targets while others like miR-205, miR-34a and miR-133b have three validated cellular targets. The table below shows the miRs along with their respective validated cellular target genes in cervical cancer.

Micro RNA	Validated cellular target genes
miR10a	HOX [9], CHL1 [10]
miR17	TP53INP1 [11]
miR19a, miR19b	CUL5 [12]
miR20a	TNKS2 [13]
miR21	PDCD4 [14,15], CCL20 [16]
miR23b	Urokinase type Plasminogen Activator (uPA) [17]
miR29a	YY1, CDK6 [18]
miR34a	Notch 1, Jagged 1 [19], p18Ink4c [20]
miR100	PLK1 [21]
miR125b	PIK3CD [22]
miR133b	MST2, CDC42 , RHOA [23]
miR143	Bcl2 [24]
miR145	IRS1 [25]
miR155	SMAD2, CCND1 [26]
miR182	FOXO1 [27]
miR196a	HOX [9]
miR205	SHIP2 [28], CYR61, CTGF [29]
miR 214	MEK3, JNK1, plexinB1, GALNT7, Bol2l2 [30-33]
miR218	LAMB3 [34-36]
miR223	FOXO1 [37]
miR302-367	CYCLIND1 [38]
miR372	CDK2, CYCLINA1 [39]
miR375	SP1 [40]
miR424	Chk1 [41]
miR497	IGF-1R [42]
miR886-5p	Bax [43]

There are about 246 miRNAs in cervical cancer that are deregulated and the cellular targets for these miRNAs have been experimentally validated. These deregulated miRNAs affect a host of cellular processes like apoptosis, cell cycle regulation, metastasis, angiogenesis etc. The complex interplay of hundreds of miRNAs ensures the development of cancerous phenotype and ultimately progression from CIN1 to CIN3 stage.

The miRNA mediated gene regulation is fast becoming a hot topic for cervical cancer research. Their ability to post transcriptionally affect diverse cellular pathways makes them good candidates for targeting

in cancer therapy. MiRNAs are also being studied for their ability to act as biomarkers for different stages of cervical cancer. Expression profile analysis for miRNAs from a patient sample can give a lot of information about the disease prognosis. More studies will reveal the detailed mechanisms by which the miRNAs gets deregulated in cervical cancer. It is important to determine the suitable miRNAs for therapeutic purpose.

References

- de Villiers EM, Gunst K, Stein H, Scherübl H. Esophageal squamous cell cancer in patients with head and neck cancer: Prevalence of human papillomavirus DNA sequences. *Int J Cancer*. 2004; 109: 253-258.
- Jansson MD, Lund AH. MicroRNA and cancer. *Mol Oncol*. 2012; 6: 590-610.
- Croce CM. Causes and consequences of microRNA dysregulation in cancer. *Nat Rev Genet*. 2009; 10: 704-714.
- Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. *Nature*. 2005; 435: 834-838.
- Munker R, Calin GA. MicroRNA profiling in cancer. *Clin Sci (Lond)*. 2011; 121: 141-158.
- Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. *Proc Natl Acad Sci USA*. 2006; 103: 2257-2261.
- Sharma G, Dua P, Agarwal SM. A Comprehensive Review of Dysregulated miRNAs Involved in Cervical Cancer. *Curr Genomics*. 2014; 15: 310-323.
- Zhao S, Yao D, Chen J, Ding N. Circulating miRNA-20a and miRNA-203 for screening lymph node metastasis in early stage cervical cancer. *Genet Test Mol Biomarkers*. 2013; 17: 631-636.
- Pereira PM, Marques JP, Soares AR, Carreto L, Santos MA. MicroRNA expression variability in human cervical tissues. *PLoS One*. 2010; 5: e11780.
- Long MJ, Wu FX, Li P, Liu M, Li X, Tang H. MicroRNA-10a targets CHL1 and promotes cell growth, migration and invasion in human cervical cancer cells. *Cancer Lett*. 2012; 324: 186-196.
- Wei Q, Li YX, Liu M, Li X, Tang H. MiR-17-5p targets TP53INP1 and regulates cell proliferation and apoptosis of cervical cancer cells. *IUBMB Life*. 2012; 64: 697-704.
- Xu XM, Wang XB, Chen MM, Liu T, Li YX, Jia WH, et al. MicroRNA-19a and -19b regulate cervical carcinoma cell proliferation and invasion by targeting CUL5. *Cancer Lett*. 2012; 322: 148-158.
- Kang HW, Wang F, Wei Q, Zhao YF, Liu M, Li X, et al. miR-20a promotes migration and invasion by regulating TNKS2 in human cervical cancer cells. *FEBS Lett*. 2012; 586: 897-904.
- Deftereos G, Corrie SR, Feng Q, Morihara J, Stern J, Hawes SE, et al. Expression of mir-21 and mir-143 in cervical specimens ranging from histologically normal through to invasive cervical cancer. *PLoS One*. 2011; 6: e28423.
- Yao Q, Xu H, Zhang QQ, Zhou H, Qu LH. MicroRNA-21 promotes cell proliferation and down-regulates the expression of programmed cell death 4 (PDCD4) in HeLa cervical carcinoma cells. *Biochem Biophys Res Commun*. 2009; 388: 539-542.
- Yao T, Lin Z. MiR-21 is involved in cervical squamous cell tumorigenesis and regulates CCL20. *Biochim Biophys Acta*. 2012; 1822: 248-260.
- Au Yeung CL, Tsang TY, Yau PL, Kwok TT. Human papillomavirus type 16 E6 induces cervical cancer cell migration through the p53/microRNA-23b/urokinase-type plasminogen activator pathway. *Oncogene*. 2011; 30: 2401-2410.
- Li Y, Wang F, Xu J, Ye F, Shen Y, Zhou J, et al. Progressive miRNA expression profiles in cervical carcinogenesis and identification of HPV-related target genes for miR-29. *J Pathol*. 2011; 224: 484-495.
- Pang RT, Leung CO, Ye TM, Liu W, Chiu PC, Lam KK, et al. MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. *Carcinogenesis*. 2010; 31: 1037-1044.
- Wang X, Meyers C, Guo M, Zheng ZM. Upregulation of p18Ink4c expression by oncogenic HPV E6 via p53-miR-34a pathway. *Int J Cancer*. 2011; 129: 1362-1372.
- Li BH, Zhou JS, Ye F, Cheng XD, Zhou CY, Lu WG, et al. Reduced miR-100 expression in cervical cancer and precursors and its carcinogenic effect through targeting PLK1 protein. *Eur J Cancer*. 2011; 47: 2166-2174.
- Cui F, Li X, Zhu X, Huang L, Huang Y, Mao C, et al. MiR-125b inhibits tumor growth and promotes apoptosis of cervical cancer cells by targeting phosphoinositide 3-kinase catalytic subunit delta. *Cell Physiol Biochem*. 2012; 30: 1310-1318.
- Qin W, Dong P, Ma C, Mitchelson K, Deng T, Zhang L, et al. MicroRNA-133b is a key promoter of cervical carcinoma development through the activation of the ERK and AKT1 pathways. *Oncogene*. 2012; 31: 4067-4075.
- Liu L, Yu X, Guo X, Tian Z, Su M, Long Y, et al. miR-143 is downregulated in cervical cancer and promotes apoptosis and inhibits tumor formation by targeting Bcl-2. *Mol Med Rep*. 2012; 5: 753-760.
- Shi M, Du L, Liu D, Qian L, Hu M, Yu M, et al. Glucocorticoid regulation of a novel HPV-E6-p53-miR-145 pathway modulates invasion and therapy resistance of cervical cancer cells. *J Pathol*. 2012; 228: 148-157.
- Lei C, Wang Y, Huang Y, Yu H, Huang Y, Wu L, et al. Up-regulated miR155 reverses the epithelial-mesenchymal transition induced by EGF and increases chemo-sensitivity to cisplatin in human Caski cervical cancer cells. *PLoS One*. 2012.
- Tang T, Wong HK, Gu W, Yu MY, To KF, Wang CC, et al. MicroRNA-182 plays an onco-miRNA role in cervical cancer. *Gynecol Oncol*. 2013; 129: 199-208.
- Witten D, Tibshirani R, Gu SG, Fire A, Lui WO. Ultra-high throughput sequencing-based small RNA discovery and discrete statistical biomarker analysis in a collection of cervical tumours and matched controls. *BMC Biol*. 2010.
- Xie H, Zhao Y, Caramuta S, Larsson C, Lui WO. miR-205 expression promotes cell proliferation and migration of human cervical cancer cells. *PLoS One*. 2012; 7: e46990.
- Yang Z, Chen S, Luan X, Li Y, Liu M, Li X, et al. MicroRNA-214 is aberrantly expressed in cervical cancers and inhibits the growth of HeLa cells. *IUBMB Life*. 2009; 61: 1075-1082.
- Qiang R, Wang F, Shi LY, Liu M, Chen S, Wan HY, et al. Plexin-B1 is a target of miR-214 in cervical cancer and promotes the growth and invasion of HeLa cells. *Int J Biochem Cell Biol*. 2011; 43: 632-641.
- Peng RQ, Wan HY, Li HF, Liu M, Li X, Tang H. MicroRNA-214 suppresses growth and invasiveness of cervical cancer cells by targeting UDP-N-acetyl- α -D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7. *J Biol Chem*. 2012; 287: 14301-14309.
- Wang F, Liu M, Li X, Tang H. MiR-214 reduces cell survival and enhances cisplatin-induced cytotoxicity via down-regulation of Bcl2L2 in cervical cancer cells. *FEBS Lett*. 2013; 587: 488-495.
- Martinez I, Gardiner AS, Board KF, Monzon FA, Edwards RP, Khan SA. Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. *Oncogene*. 2008; 27: 2575-2582.
- Yamamoto N, Kinoshita T, Nohata N, Itesako T, Yoshino H, Enokida H, et al. Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion by targeting focal adhesion pathways in cervical squamous cell carcinoma. *Int J Oncol*. 2013; 42: 1523-1532.
- Li Y, Liu J, Yuan C, Cui B, Zou X, Qiao Y. High-risk human papillomavirus reduces the expression of microRNA-218 in women with cervical intraepithelial neoplasia. *J Int Med Res*. 2010; 38: 1730-1736.
- Wu L, Li H, Jia CY, Cheng W, Yu M, Peng M, et al. MicroRNA-223 regulates FOXO1 expression and cell proliferation. *FEBS Lett*. 2012; 586: 1038-1043.

38. Cai N, Wang YD, Zheng PS. The microRNA-302-367 cluster suppresses the proliferation of cervical carcinoma cells through the novel target AKT1. *RNA*. 2013; 19: 85-95.
39. Tian RQ, Wang XH, Hou LJ, Jia WH, Yang Q, Li YX, et al. MicroRNA-372 is down-regulated and targets cyclin-dependent kinase 2 (CDK2) and cyclin A1 in human cervical cancer, which may contribute to tumorigenesis. *J Biol Chem*. 2011; 286: 25556-25563.
40. Wang F, Li Y, Zhou J, Xu J, Peng C, Ye F, et al. miR-375 is down-regulated in squamous cervical cancer and inhibits cell migration and invasion via targeting transcription factor SP1. *Am J Pathol*. 2011; 179: 2580-2588.
41. Xu J, Li Y, Wang F, Wang X, Cheng B, Ye F, et al. Suppressed miR-424 expression via upregulation of target gene Chk1 contributes to the progression of cervical cancer. *Oncogene*. 2013; 32: 976-987.
42. Luo M, Shen D, Zhou X, Chen X, Wang W. MicroRNA-497 is a potential prognostic marker in human cervical cancer and functions as a tumor suppressor by targeting the insulin-like growth factor 1 receptor. *Surgery*. 2013; 153: 836-847.
43. Li JH, Xiao X, Zhang YN, Wang YM, Feng LM, Wu YM, et al. MicroRNA miR-886-5p inhibits apoptosis by down-regulating Bax expression in human cervical carcinoma cells. *Gynecol Oncol*. 2011; 120: 145-151.